Certara Corporation Launches Cardiac Safety Simulator to Determine Likelihood That New Drug Candidates Could Cause Potentially-Fatal Arrhythmias

Published: Aug 01, 2013

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ST. LOUIS--(BUSINESS WIRE)--Certara™, a leading provider of software and scientific consulting services to improve productivity and decision-making from drug discovery through drug development, today announced the launch of its Cardiac Safety Simulator™ (CSS), based on an in-silico model of human ventricular heart cells. When the CSS is integrated with Certara’s Simcyp™ Population-based Simulator, it allows for the in-vitro to in-vivo extrapolation of the pharmacokinetic and pharmacodynamic data to predict the likelihood that a drug candidate will exhibit cardiac toxicity.

Help employers find you! Check out all the jobs and post your resume.

Back to news